Acurx Pharmaceuticals: Promising Developments and Strategic Advances in Antibiotic Innovation

Tip Ranks
2025.11.13 16:45
portai
I'm PortAI, I can summarize articles.

Analyst Jason McCarthy from Maxim Group maintains a Buy rating on Acurx Pharmaceuticals with a $30 price target, citing promising developments in ibezapolstat, a new antibiotic class targeting C. difficile infection. The drug shows low gut microbiome disruption and high clinical cure rates in Phase 2b trials. Positive regulatory feedback supports Phase 3 trials. McCarthy's optimistic outlook is shared by H.C. Wainwright, which also rates the stock as Buy with a $31 target.

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Acurx Pharmaceuticals. The associated price target is $30.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Jason McCarthy has given his Buy rating due to a combination of factors including Acurx Pharmaceuticals’ promising developments with ibezapolstat, a new class of antibiotic targeting C. difficile infection. The drug has shown a low risk of disrupting the gut microbiome compared to other antibiotics, which is a significant advantage. Additionally, recent data presented at the IDWeek 2025 Scientific Conference and published in ‘Nature Communications’ highlight the drug’s unique mechanism of action and potential benefits.
Furthermore, Acurx has made significant progress in its clinical trials, with a high clinical cure rate observed in Phase 2b studies. The company has also received positive regulatory feedback from both the FDA and EU regulators, paving the way for Phase 3 trials. These developments, combined with the strategic importance of developing new antimicrobials domestically, contribute to McCarthy’s optimistic outlook on the company’s future prospects.

According to TipRanks, McCarthy is an analyst with an average return of -14.4% and a 33.20% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SCYNEXIS, Neuphoria Therapeutics, and OS Therapies Incorporated.

In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $31.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.